One To Watch
Revier Therapeutics
Company Overview
A Heidelberg University spinout pioneering selective class IIa HDAC inhibitors for cardiometabolic disease, with lead programs in heart failure with preserved ejection fraction and atherosclerotic cardiovascular disease. Revier Therapeutics emerged from stealth in August 2026, announcing a EUR 6 million seed financing alongside its public launch. The company claims the first therapeutic approach to selectively target class IIa histone deacetylases, a target class that has attracted scientific interest but resisted selective pharmacological control until now.
Headquarters and Global Presence
Revier Therapeutics is based in Heidelberg, Germany, and spun out of Heidelberg University. Its scientific leadership maintains academic ties to Heidelberg University and University Medical Center Utrecht, giving the company a foothold in two of Europe's leading cardiovascular research ecosystems.
Founding and History
Revier was founded as a spinout of Heidelberg University, with its scientific origin rooted in the work of Prof. Johannes Backs at the Institute of Experimental Cardiology. The company operated in stealth before emerging publicly in August 2026 with the close of its EUR 6 million seed round.
Therapy Areas and Focus
Revier's primary focus is cardiometabolic disease, a broad category where mechanistic understanding has outpaced drug development for decades. Its lead program targets heart failure with preserved ejection fraction, a form of heart failure representing roughly half of all cases and for which treatment options remain severely limited. Its second program addresses atherosclerotic cardiovascular disease, the leading cause of death globally. Both indications share an underlying biology that the company believes is amenable to class IIa HDAC modulation.
Technology Platforms and Modalities
Revier's approach centers on first-in-class small molecules that selectively inhibit the disease-driving enzymatic activity of class IIa HDACs without disrupting their essential structural and scaffolding functions. This selectivity is the core scientific claim: existing HDAC inhibitors in clinical use target class I HDACs and carry significant toxicity, while non-selective pan-HDAC inhibition produces on-target adverse effects that have limited the class in non-oncology settings. By sparing both the canonical functions of class IIa HDACs and the activity of class I HDACs, Revier aims for a cleaner therapeutic window. The small-molecule modality keeps the program compatible with oral dosing, which matters commercially in chronic cardiometabolic conditions.
Key Pipeline and Programs
The lead program targets heart failure with preserved ejection fraction. HFpEF is mechanistically heterogeneous and has defeated multiple Phase III trials in recent years, but growing evidence links pathological cardiac remodeling to aberrant class IIa HDAC activity, particularly HDAC4 and HDAC5. Revier's compounds aim to inhibit the deacetylase-dependent signaling that drives this remodeling. Both programs are at the preclinical stage, with seed proceeds earmarked to advance them toward clinical candidacy.
The second program targets atherosclerotic cardiovascular disease. The rationale for class IIa HDAC involvement in ASCVD relates to inflammatory and metabolic gene regulation in vascular and metabolic tissues. No clinical-stage assets or trial identifiers have been disclosed at this stage. The EUR 6 million seed financing is intended to fund preclinical advancement across both programs, with the implied goal of generating data sufficient to support a larger Series A raise.
Recent Developments
In August 2026, Revier announced its public launch and the close of a EUR 6 million seed financing round. The round was led by KHAN Technology Transfer Fund II, with participation from High-Tech Gruenderfonds, VORNvc, and private investors through Revier Invest Heidelberg. Both programs are preclinical, and the company has not yet disclosed development timelines or target candidate nomination dates. The launch itself is the material event: Revier is a new entrant with a novel mechanistic thesis in a therapy area that commands strong commercial and scientific attention.
Key Personnel
Prof. Eva van Rooij, PhD, serves as Chief Executive Officer. She is a serial biotechnology entrepreneur and Professor of Molecular Cardiology at University Medical Center Utrecht, with extensive experience in cardiovascular translational research. Prof. Johannes Backs, MD, is the company's Scientific Founder and Director of the Institute of Experimental Cardiology at Heidelberg University, where the core science originated.
Strategic Partnerships
The seed round was led by KHAN Technology Transfer Fund II, a technology transfer-focused investor, with co-investment from High-Tech Gruenderfonds and VORNvc, alongside private investors channeled through Revier Invest Heidelberg. No licensing deals, pharma collaborations, or research partnerships beyond the academic ties to Heidelberg University and University Medical Center Utrecht have been announced at this stage.
FAQ Section
Approved HDAC inhibitors, such as vorinostat and romidepsin, act on class I HDACs and carry a toxicity profile that has confined them to oncology. Class IIa HDACs play a distinct, tissue-specific role in cardiac and metabolic gene regulation, and Revier's thesis is that selectively inhibiting their enzymatic activity, without touching class I HDACs or the structural functions of class IIa HDACs, could unlock a safer therapeutic window suited to chronic cardiometabolic use.
HFpEF is defined by diastolic dysfunction with a preserved left ventricular ejection fraction, and its molecular drivers are heterogeneous, which is why multiple large Phase III trials targeting neurohormonal and metabolic pathways have failed to show clear benefit. Class IIa HDACs, particularly HDAC4 and HDAC5, shuttle between the nucleus and cytoplasm in response to cardiac stress signals, regulating gene programs that govern cardiac remodeling. Inhibiting the pathological arm of that activity while preserving normal function is where Revier's selectivity claim carries its greatest weight.
Earlier efforts at HDAC inhibition in cardiovascular disease were hampered by compounds that could not distinguish between the deacetylase-dependent disease activity of class IIa HDACs and their essential scaffolding and protein-interaction roles, producing unacceptable off-target effects. Revier's core claim is functional selectivity within the class IIa subgroup itself, preserving the structural functions while blocking the enzymatic activity that drives pathological remodeling. If the preclinical data support that claim, it would represent a meaningful pharmacological advance over what has been tried before.
The lead program is at the preclinical stage, and the EUR 6 million seed financing is intended to advance it toward a clinical candidate nomination. No IND filing date, trial identifier, or target candidate milestone has been publicly disclosed. The immediate task funded by the round is generating the mechanistic and efficacy data needed to nominate a development compound and support a larger financing to take it into the clinic.
Revier's announced pipeline spans two cardiovascular and metabolic indications: HFpEF and atherosclerotic cardiovascular disease. Both sit within the broader cardiometabolic space, and the shared biology of class IIa HDAC regulation in cardiac, vascular, and metabolic tissues suggests the platform could extend into other cardiometabolic conditions over time. The company has not publicly signaled plans beyond these two initial programs at this stage.
Revier is a preclinical-stage company that emerged from stealth in August 2026 with its first external financing in place. Near-term milestones will center on advancing its HFpEF and ASCVD programs through target validation and lead optimization toward clinical candidate nomination. A successful candidate nomination in either program would be the trigger for a larger Series A financing and the beginning of a formal IND-enabling study program.
Revier is an early-stage company with an unproven but scientifically grounded thesis, and the watchpoints cut both ways. Key items to monitor include:
- Preclinical proof-of-concept data demonstrating functional selectivity within the class IIa HDAC subgroup and efficacy in HFpEF or ASCVD disease models.
- Clinical candidate nomination in the lead HFpEF program, which would mark the transition from discovery to development and signal readiness for a larger financing round.
- The risk that the selectivity claim does not translate: if inhibiting the enzymatic activity of class IIa HDACs cannot be cleanly separated from their structural roles in vivo, the therapeutic window could prove narrower than the preclinical hypothesis suggests.
- Competitive dynamics in HFpEF, where multiple modalities including GLP-1 agonists, SGLT2 inhibitors, and novel small molecules are advancing, raising the bar for differentiation.
- Financing runway: EUR 6 million is a lean seed for a preclinical cardiometabolic program, and the pace of progression will depend on how quickly the company can generate data to justify its next raise.
Latest Revier Therapeutics News
Today's issue
| Headless Content Management with Blaze